Lindbrook Capital’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Lindbrook Capital’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-69	Closed	-$2.41K	–	2874
2024 Q1	$2.41K	Hold	69	–	–	﹤0.01%	2172
2023 Q4	$2.62K	Sell	69 -34	-33%	-$729	﹤0.01%	2169
2023 Q3	$1.89K	Buy	+103	New	+$2.15K	﹤0.01%	2150
2023 Q1	–	Sell	-74	Closed	-$1.82K	–	2990
2022 Q4	$1.82K	Buy	74 +33	+80%	+$970	﹤0.01%	2271
2022 Q3	$1K	Sell	41 -104	-72%	-$1.88K	﹤0.01%	2593
2022 Q2	$2K	Buy	145 +67	+86%	+$986	﹤0.01%	2120
2022 Q1	$2K	Buy	+78	New	+$1.99K	﹤0.01%	2145

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Lindbrook Capital's INBX Position: Q2 2024 in Review

Lindbrook Capital sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 69 shares — an estimated $2.41K sold.

Lindbrook Capital first reported a position in INBX in Q1 2022 and held it in 7 quarters. The position peaked at $2.62K in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Lindbrook Capital reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Lindbrook Capital sold 69 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $2.41K.
Lindbrook Capital first reported a position in Inhibrx, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Lindbrook Capital's Inhibrx, Inc. Common Stock position peaked at $2.62K in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.